Sitemap
- Home
- Rare Blood Disorders
- Rare Disease
- Other topics
- Vaccines and Immunization
- Products
- Avalide® (irbesartan-hydrochlorothiazide)
- Sarclisa® (isatuximab-irfc) injection for intravenous use
- ZALTRAP (ziv-aflibercept) injection for intravenous infusion
- Admelog® (Insulin Lispro) Injection 100 Units/mL
- Elitek® (rasburicase) for injection
- FAQs
- Prophylactic Use of ELITEK® (rasburicase) IV Infusion Was Studied in Pediatric Patients
- ELITEK® (rasburicase) IV Infusion Once Daily for Up To 5 Days1
- TLS: An Oncologic Emergency with Potentially Devastating Consequences
- ELITEK® (rasburicase) IV Infusion Has a Proven Safety Profile
- Protect against rising uric acid levels in high-risk adult patients
- Unlike Allopurinol, ELITEK® (rasburicase) IV Infusion Clears New and Existing Uric Acid1
- Various Factors Increase the Risk of Developing TLS1-3
- ELITEK® (rasburicase) IV Infusion Was Studied in Adults at High and Intermediate (Potential) Risk of TLS1
Protect Pediatric Patients at Risk from Rising Uric Acid Levels
Resources at the Ready
- Cerezyme® (imiglucerase) for injection
Gaucher Disease Type 1 Symptoms, Diagnosis & Testing
Cerezyme® (imiglucerase) 6-Month Pivotal Study
Gaucher Disease Type 1 Prevalence
Cerezyme® (imiglucerase) 8-Year Pediatric Study
Cerezyme® (imiglucerase) Bone Studies
Cerezyme® (imiglucerase) 20-Year Gaucher Registry Analysis
CareConnect™ Personalized Support Services
Treatment Options for Gaucher Disease Type 1
Request a Cerezyme® (imilgucerase) Representative
Cerezyme® (imiglucerase) Studies Overview
Cerezyme® (imiglucerase) Mechanism of Action
Cerezyme® (imiglucerase) Dosing and Administration
Cerezyme® (imiglucerase) Safety Profile and Side Effects
Cerezyme® (imiglucerase) Access, Billing, and Reimbursement
The International Collaborative Gaucher Group (ICGG) Gaucher Registry
Resources for Physicians
- Cerdelga® (eliglustat) capsules
- Cerdelga® (eliglustat) Mechanism of Action
- Cerdelga® (eliglustat) ERT Switch Patient Trial
- Cerdelga® (eliglustat) Treatment-naive Patient Trials
- Resources for Physicians
Request a Cerdelga® (eliglustat) Representative
- Gaucher Signs and Symptoms
- Gaucher Inheritance and Prevalence
- Cerdelga® (eliglustat) Eligibility Testing
- Cerdelga® (eliglustat) Dosing
- Cerdelga® (eliglustat) Osteonecrosis Retrospective Study
- CareConnect™ Personalized Support Services
- Gaucher Testing and Diagnosing
- Ambien® (zolpidem tartrate) tablets
- Priftin (rifapentine) tablets
- Lantus® (insulin glargine injection) 100 Units/mL
- Pentacel® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine
- MERILOG (insulin aspart-szjj) injection 100 Units/mL
- Sanofiflu
WHAT IS FLUZONE® (INFLUENZA VACCINE)?
FLUZONE® HIGH-DOSE (INFLUENZA VACCINE): OVERVIEW OF EFFICACY AND SAFETY
FLUBLOK® (INFLUENZA VACCINE): OVERVIEW OF EFFICACY AND SAFETY
- TALK TO YOUR PATIENTS ABOUT THE FLU
CODING & BILLING FOR THE 2025/2026 SEASON
- RESOURCES TO HELP SUPPORT YOUR PATIENTS AND PRACTICE THIS FLU SEASON
- LEMTRADA® (alemtuzumab)
- Kevzara® (sarilumab) injection
- Rifadin® IV (rifampin for injection, USP)
- Aldurazyme® (laronidase)
Aldurazyme® (laronidase) Safety Profile and Side Effects
CareConnectTM Personalized Support Services
Request an Aldurazyme® (laronidase) representative
Aldurazyme® (laronidase) Mechanism of Action
Resources for Physicians
Mucopolysaccharidosis type I (MPS I) Diagnosis
- Aldurazyme® (laronidase) Billing and Reimbursement
Aldurazyme® (laronidase) Clinical Trial Results
Mucopolysaccharidosis type I (MPS I) Disease Overview
Mucopolysaccharidosis type I (MPS I) Organizations & Resources
- Aldurazyme® (laronidase) Dosing and Administration
Aldurazyme® (laronidase) Copay Program
Mucopolysaccharidosis type I (MPS I) Monitoring
- Aldurazyme® (laronidase) Continuing with Care
- WAYRILZ (rilzabrutinib)
WAYRILZ™ (rilzabrutinib) Mechanism of Action
WAYRILZ™ (rilzabrutinib): LUNA-3 Clinical Study Design
Mechanism of Disease
Thank you for connecting with us!
Contact a Representative
Unmet Needs
Efficacy for WAYRILZ™ (rilzabrutinib)
WAYRILZ™ (rilzabrutinib) Patient Resources
Patient Profiles
Dosing for WAYRILZ™ (rilzabrutinib)
Burden of ITP
Safety information on WAYRILZ™ (rilzabrutinib)
- Apidra® (Insulin Glulisine) Injection 100 units/mL
- Ferrlecit® (sodium ferric gluconate complex in sucrose injection)
- Beyfortus® (nirsevimab-alip)
Beyfortus® (nirsevimab-alip) Efficacy and Safety Profile Overview
One Last Step
- Dosing & Administration
- Articles
What Is RSV?
Respiratory Syncytial Virus (RSV) Activity in Your Area
Request a Representative
Resources
- Articles
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Frequently Asked Questions
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Frequently Asked Questions
Mechanism of Action for Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection
Thank You for Connecting With Us!
- Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection Resources
How to Order
- Real-World Evidence
Tested, Trusted, and Demonstrated - Cost & Coverage
Sign Up for the Latest Updates
Information for OB-GYNS
- Plavix® (clopidogrel bisulfate)
- JEVTANA® (cabazitaxel) injection
- JEVTANA® (cabazitaxel) injection: PROSELICA Trial - Efficacy & Safety Overview
- The CARD Trial Was the First Comparative, Prospective, Phase 4 Trial Evaluating JEVTANA® (cabazitaxel) injection vs Abiraterone or Enzalutamide1,2
- Understanding Mechanisms of Progression For Prostate Cancer
- JEVTANA® (cabazitaxel) injection Preparation & Administration1
- DURATION OF THERAPY
- JEVTANA® (cabazitaxel) injection Dosing and Dose Modifications1
- JEVTANA® (cabazitaxel) injection Is a Microtubule Inhibitor1,2
- PROSELICA Results Established JEVTANA® (cabazitaxel) injection 20 mg/m2 as the Recommended Dose1,2
- JEVTANA® (cabazitaxel) injection: CARD Trial - Efficacy & Safety Overview
- JEVTANA® (cabazitaxel) injection Is a National Comprehensive Cancer Network® (NCCN® ) Designated Category 1 Preferred Regimen following Docetaxel and Novel Hormonal Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).1
- TROPIC Results Validated JEVTANA® (cabazitaxel) injection as a 2nd-Line Treatment After Docetaxel in a Pivotal Phase 3 Trial vs Mitoxantrone1,2
- Pick a CARD
- The National Comprehensive Cancer Network® (NCCN® ) and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) Recommend mCRPC Patients Be Monitored Closely for Progression1,2
- JEVTANA® (cabazitaxel) injection: TROPIC Trial - Efficacy & Safety Overview
- CABLIVI (caplacizumab-yhdp)
- Prescribe CABLIVI® (caplacizumab-yhdp) with confidence
- Results with CABLIVI® (caplacizumab-yhdp)
- Resources for diagnosis
- CABLIVI® (caplacizumab-yhdp) Patient Solutions
- CABLIVI® (caplacizumab-yhdp) coverage and reimbursement*
Support for your patients from HemAssist
CABLIVI is the first and only therapy targeted to prevent microthrombi in adults with aTTP/iTTP1,2
- Resources for your patients
- The CABLIVI® (caplacizumab-yhdp) dosing regimen
Help your patients with aTTP/iTTP transition from hospital to home with CABLIVI® (caplacizumab-yhdp)
- Contact a CABLIVI® (caplacizumab-yhdp) representative
- Differentiating aTTP/iTTP
Access CABLIVI® (caplacizumab-yhdp) quickly and efficiently
- Resources for treating with CABLIVI® (caplacizumab-yhdp)
aTTP/iTTP is a rare, life-threatening medical emergency1-6
ISTH Guidelines recommend CABLIVI® (caplacizumab-yhdp) for acute aTTP/iTTP events—initial and relapsing1,2
Patient support for CABLIVI®
aTTP/iTTP is a medical emergency and early diagnosis is critical1,2
- Reconstituting and administering CABLIVI® (caplacizumab-yhdp)
- Qfitlia™ (fitusiran)
- Mechanism of action: how Qfitlia™ (fitusiran) helps restore hemostasis by lowering antithrombin for people with hemophilia1
Dosing for Qfitlia™ (fitusiran) is guided by antithrombin levels1
Patient support for Qfitlia™
Safety information and adverse events on Qfitlia™ (fitusiran)
- INTERACTIVE DOSING TOOL FOR QFITLIA™
- Qfitlia™ (fitusiran) resources for healthcare professionals
Qfitlia™ (fitusiran) offers proven bleed protection with as few as 6 injections a year1
- Qfitlia™ (fitusiran): illustrative patient profiles
Supporting your patients with HemAssist™
- Qfitlia™ (fitusiran): Contact a representative
Manage breakthrough bleeds with reduced doses and frequency of factor or BPA1*†
- Qfitlia™ (fitusiran): ATLAS clinical trial design
- ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein]
ELOCTATE®—Powered by Fc Fusion
Clinical Challenges of Hemophilia Treatment
ELOCTATE®—Powered by Fc Fusion
ELOCTATE® Has an Established Safety Profile1
CHANGES IN JOINT HEALTH WERE EVALUATED1
HemAssistTM Sanofi Support
BLEED AND JOINT BLEED PROTECTION WITH ELOCTATE®1*
Bleed and joint bleed protection with ELOCTATE®
Request a Visit From Your ELOCTATE® Representative
Resources for your practice
CHANGES IN JOINT HEALTH WERE EVALUATED1
Patient support for ELOCTATE®
- Xenpozyme® (olipudase alfa-rpcp) for injection, 20mg
- ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl]
Your request has been submitted
- Clinical Cases
- Hemophilia A Case Study: Noah
- HCP resources
- Hemophilia A Case Study: Henry
- Contact a Representative
- Adult & Adolescent Study - Efficacy
- Pediatric Study - Trial Design
- About Hemophilia A
- Adult & Adolescent Study - Pharmacokinetics
- Dosing Calculator
- Hemophilia A Case Study: Aaron
- Surgical Data in Patients with Hemophilia A
HemAssistTM Sanofi Support
- Pediatric Study - Safety
Patient support for ALTUVIIIO®
- Adult & Adolescent Study - Safety
- Dosing regimen
- Hemophilia A Case Study: Peter
- Hemophilia A Case Study: Sean
- Pediatric Study - Results
- Hemophilia A Case Study: Otis
- Surgical Data in Patients with Hemophilia A
- Pediatric Study - Pharmacokinetics
- Mechanism of half-life extension (MOE)
- Adult & Adolescent Study - Trial Design
- Ambien CR® (zolpidem tartrate) extended-release tablets
- Renvela® (sevelamer carbonate)
- Tzield® (teplizumab-mzwv) injection 2mg/2mL
- Sanofi Vaccines Portfolio
The impact of respiratory illnesses
The Sanofi Immunization Portfolio offers a broad range of products
- Helping to protect your pediatric patients
Sanofi Immunization Portfolio: Your partner in pediatric protection
The Sanofi Immunization Portfolio can help to protect your adult patients
Unique educational resources for your practice and your patients
Partnering to help keep your patients healthy
Contact a Sales Specialist: Sanofi can help support your practice along the way
Addressing vaccine hesitancy
How the Sanofi Pediatric Portfolio may benefit your patients and your practice
- Insulin Portfolio
- Dupixent® (dupilumab) injection
- Flomax® (tamsulosin HCI) capsules
- Caprelsa® (vandetanib) Tablets
- Clolar® (clofarabine injection)
- HemAssist™
- Synvisc-One® (hylan G-F 20)
- Toujeo® (insulin glargine injection) 300 Units/mL
- Amaryl® (glimepiride tablets)
- Hectorol® (doxercalciferol) injection
- Avapro® (irbesartan)
- Fabrazyme® (agalsidase beta)
Fabrazyme® (agalsidase beta) Efficacy: Effect on Clinically Significant Events
- Fabrazyme® (agalsidase beta) Safety
- Resources for Physicians
- CareConnect™ Personalized Support Services
- Fabrazyme® (agalsidase beta) for Females with Fabry
- Fabry Registry
- Fabrazyme® (agalsidase beta) for Children with Fabry
- Fabry Disease Overview
- Fabrazyme® (agalsidase beta): Financial Assistance, Billing, and Reimbursement
- Fabrazyme® (agalsidase beta) Mechanism of Action
- Fabrazyme® (agalsidase beta) Efficacy: Renal Data
- Fabrazyme® (agalsidase beta): 20 Years of Real-World Experience
- Fabrazyme® (agalsidase beta) Efficacy: GL-3 Clearance
- Think Fabrazyme® (agalsidase beta) First for All
- Fabrazyme® (agalsidase beta) Dosing and Administration
Request a Fabrazyme® (agalsidase beta) Representative
- Arava® Tablets (leflunomide)
- Lumizyme® (alglucosidase alfa)
Starting Lumizyme® (alglucosidase alfa)
CareConnectTM Personalized Support Services
Request a Lumizyme® (alglucosidase alfa) Representative
Request a Lumizyme® (alglucosidase alfa) Representative
Downloadable Resources about Lumizyme® (alglucosidase alfa)
Lumizyme® (alglucosidase alfa) Late-Onset Pompe Disease (LOPD) Trials
Lumizyme® (alglucosidase alfa) Mechanism of Action
Lumizyme® (alglucosidase alfa) Infantile-Onset Pompe Disease (IOPD) Trials
Pompe Disease Overview
- Aubagio® (teriflunomide)
- Mozobil® (Plerixafor) Injection
- Synvisc® (hylan G-F 20)
- Thyrogen® (thyrotropin alfa) for injection
- Thyrogen® (thyrotropin alfa) for injection Financial Assistance Programs for your Eligible Patients
- How to Order Thyrogen® (thyrotropin alfa) for injection, for your Patients
- Thyrogen® (thyrotropin alfa) for injection Efficacy in Radioactive Iodine Ablation (RAI)
- Thyrogen® (thyrotropin alfa) for injection Use in Post Surgical Risk Assessment
Physician and Patient Perspectives
- Resources for Thyrogen® (thyrotropin alfa) for injection
- Safety Profile of Thyrogen® (thyrotropin alfa) for injection
- Clinical Pharmacology of Thyrogen® (thyrotropin alfa) for injection
- Thyroid Hormone Withdrawal (THW) May Cause Acute Hypothyroidism1
- Thyrogen® (thyrotropin alfa) for injection Efficacy in Diagnostic Testing
- Administration of Thyrogen® (thyrotropin alfa) for injection, for intramuscular use
- Coverage and Support for Thyrogen® (thyrotropin alfa) for injection
- Thyrogen® (thyrotropin alfa) for injection Helps Maintain Function
- Nexviazyme™ (avalglucosidase alfa-ngpt)
- Nuvaxovidᵀᴹ (COVID-19 Vaccine, Adjuvanted)
- POWERFUL PROTECTION AGAINST COVID-191
NUVAXOVID HAD LOW REACTOGENICITY IN CLINICAL TRIALS AND MINIMALLY DISRUPTIVE SIDE EFFECTS1,2
CONVENIENT STORAGE AND ADMINISTRATION WITH NUVAXOVID.1
- THE ONLY FDA-APPROVED, non-mRNA COVID-19 VACCINE1,2
YOUR RECOMMENDATION CAN HELP PATIENTS CHOOSE THE PROTECTION OF A COVID-19 VACCINE1
- ORDER NUVAXOVID AND ACCESS RESOURCES FOR YOU AND YOUR PATIENTS
- MULTAQ (dronedarone)
- Thymoglobulin® [Anti-thymocyte Globulin (Rabbit)]
- Rezurock (belumosudil) tablets
- Renagel® Tablets (sevelamer hydrochloride) 800mg tablets
- Lovenox® (enoxaparin sodium injection) - 2
- HemAssist™
- Primaquine® (Primaquine Phosphate Tablets)
- ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein]
- ALPROLIX® offers effective hemostatic control for both major and minor surgeries1
- Demonstrated safety profile for ALPROLIX® for patients across all ages and settings1
Resources for Healthcare Professionals
Patient support for ALPROLIX®
- Your request has been submitted
ALPROLIX Dosing
- On-demand dosing with ALPROLIX® can be used to control your patients' bleeding episodes1
Prophylaxis for PTPs
- Extravascular distribution
About Factor IX
- Fc Fusion allows ALPROLIX® to mirror the pathway followed by endogenous factor IX
Prophylaxis for PUPs
Mechanism of Extension
Adult & Adolescent Efficacy
- ALPROLIX® prophylaxis has extended dosing vs SHLs that helps reduce the treatment burden1,2
- ALPROLIX® offers hemostatic control for both major and minor surgeries1
- ALPROLIX® has a decade of experience your patients can trust1
Pediatric Efficacy
- Bleed reduction observed in real-world SHL switches1
- Contact a Representative
- Soliqua® 100/33 (insulin glargine and lixisenatide) injection 100 Units/mL and 33 mcg/mL
- Therapeutic Areas
- Sitemap
- Terms of Use
- Privacy Policy
- Cookie Policy
